First-in-human uPAR PET: Imaging of Cancer Aggressiveness
Open accessThe DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
A first-in-human clinical trial with Positron Emission Tomography (PET) imaging of the urokinase-type plasminogen activator receptor (uPAR) in patients with breast, prostate and bladder cancer, is described. uPAR is expressed in many types of human cancers and the expression is predictive of invasion, metastasis and indicates poor prognosis. uPAR PET imaging therefore holds promise to be a new and innovative method for improved cancer diagnosis, staging and individual risk stratification. The uPAR specific peptide AE105 was conjugated to the macrocyclic chelator DOTA and labeled with (64)Cu for targeted molecular imaging with PET. The safety, pharmacokinetic, biodistribution profile and radiation dosimetry after a single intravenous dose of (64)Cu-DOTA-AE105 were assessed by serial PET and computed tomography (CT) in 4 prostate, 3 breast and 3 bladder cancer patients. Safety assessment with laboratory blood screening tests was performed before and after PET ligand injection. In a subgroup of the patients, the in vivo stability of our targeted PET ligand was determined in collected blood and urine. No adverse or clinically detectable side effects in any of the 10 patients were found. The ligand exhibited good in vivo stability and fast clearance from plasma and tissue compartments by renal excretion. In addition, high uptake in both primary tumor lesions and lymph node metastases was seen and paralleled high uPAR expression in excised tumor tissue. Overall, this first-in-human study therefore provides promising evidence for safe use of (64)Cu-DOTA-AE105 for uPAR PET imaging in cancer patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Wadas, T. J., Eiblmaier, M., Zheleznyak, A., Sherman, C. D., Ferdani, R., Liang, K., Achilefu, S., & Anderson, C. J. (2008) · Journal of Nuclear Medicine · doi:10.2967/jnumed.108.054502 · Cited by 73
Cited by
ImmunoPET: Concept, Design, and Applications
Wei, W., Rosenkrans, Z. T., Liu, J., Huang, G., Luo, Q.-Y., & Cai, W. (2020) · Chemical Reviews · doi:10.1021/acs.chemrev.9b00738 · Cited by 484
Mahmood, N., Mihalcioiu, C., & Rabbani, S. A. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00024 · Cited by 478
Radiopharmaceuticals and their applications in medicine
Zhang, S., Wang, X., Gao, X., Chen, X., Li, L., Li, G., Liu, C., Miao, Y., Wang, R., & Hu, K. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02041-6 · Cited by 284
Shao, L., Liu, Z., Feng, L., Lou, X., Li, Z., Zhang, X.-Y., Wan, X., Zhou, X., Sun, K., Zhang, D.-F., et al. (2020) · Annals of Surgical Oncology · doi:10.1245/s10434-020-08659-4 · Cited by 92
Metrangolo, V., Ploug, M., & Engelholm, L. H. (2021) · Cancers · doi:10.3390/cancers13215376 · Cited by 44
“The design and implementation of theranostic approaches combining uPAR-targeted therapeutic and non-invasive imaging modalities, such as positron emission tomography (PET), magnetic resonance (MRI), or near-infrared (NIR) fluorescence imaging, are currently underway and hold clinical potential for significantly improv…”
BackgroundSelf-citation
Metadata
- Authors
- Persson, M., Skovgaard, D., Brandt-Larsen, M., Christensen, C., Madsen, J., Nielsen, C. H., Thurison, T., Klausen, T. L., Holm, S., Loft, A., Berthelsen, A. K., Ploug, M., Pappot, H., Brasso, K., Kroman, N., Højgaard, L., & Kjaer, A.
- Venue
- Theranostics
- Publisher
- Ivyspring International Publisher
- Published
- 2015
- Volume
- 5
- Issue
- 12
- Pages
- 1303-1316
- ISSN
- 1838-7640 (ISSN-L)
- OpenAlex
- W2395284164
- Cited by
- 114
- References
- 1
- FWCI
- 6.65
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: First-in-human uPAR PET: Imaging of Cancer Aggressiveness. https://app.cochat.ai/papers/10.7150/thno.12956
- The paper
- Persson, M., Skovgaard, D., Brandt-Larsen, M., Christensen, C., Madsen, J., Nielsen, C. H., Thurison, T., Klausen, T. L., Holm, S., Loft, A., Berthelsen, A. K., Ploug, M., Pappot, H., Brasso, K., Kroman, N., Højgaard, L., & Kjaer, A. (2015). First-in-human uPAR PET: Imaging of Cancer Aggressiveness. Theranostics. https://doi.org/10.7150/thno.12956
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.